Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Addressing the Role of Conventional CD8αβ+ T Cells and CD4+ T Cells in Intestinal Immunopathology Using a Bone Marrow-Engrafted Model
Publication Year: 2024 Source: Bio Protoc PMID: 38405082 DOI: 10.21769/BioProtoc.4934
Inflammatory bowel disease (IBD) is characterized by an aberrant immune response against microbiota. It is well established that T cells play a critical role in mediating the pathology. Assessing the contribution of each subset of T cells in mediating the pathology is crucial in order to design better therapeutic strategies. …
Infliximab Therapeutic monitoring by tryptic peptide LC-MS/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time
Publication Year: 2024 Source: J Mass Spectrom Adv Clin Lab PMID: 38405411
No Abstract
Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review
Publication Year: 2024 Source: Front Pharmacol PMID: 38405669
No Abstract
Accessible chromatin maps of inflammatory bowel disease intestine nominate cell-type mediators of genetic disease risk
Publication Year: 2024 Source: bioRxiv PMID: 38405748 DOI: 10.1101/2024.02.09.579678
Inflammatory Bowel Disease ( IBD ) is a chronic and often debilitating autoinflammatory condition, with an increasing incidence in children. Standard-of-care therapies lead to sustained transmural healing and clinical remission in fewer than one-third of patients. For children, TNFalpha inhibition remains the only FDA-approved biologic therapy, providing an even greater …
TL1A/DR3 signaling regulates the generation of pathogenic Th9 cells in experimental inflammatory bowel disease
Publication Year: 2024 Source: bioRxiv PMID: 38405912 DOI: 10.1101/2024.02.09.579684
OBJECTIVE: Death receptor 3 (DR3) and its ligand tumor necrosis factor like ligand 1A (TL1A), are involved in the regulation of the balance between effector and regulatory T cells in IBD. New evidence suggests a role of IL-9-secreting Th9 cells in the pathogenesis of ulcerative colitis (UC), although the molecular …
Lichen Planopilaris As Part of Multiple Autoimmune Syndrome: A Case Report of New Association
Publication Year: 2024 Source: Cureus PMID: 38406152 DOI: 10.7759/cureus.52892
Lichen planopilaris (LPP) is an uncommon inflammatory scalp condition. Its typical clinical presentation includes scaly, erythematous plaques resulting in irreversible alopecia. In this study, we report a female in her late 30s with hypothyroidism and Crohn's disease. She presented with gradual, localized hair loss that had been ongoing for the …
Appraising the causal association between Crohn's disease and breast cancer: a Mendelian randomization study
Publication Year: 2024 Source: Front Oncol PMID: 38406175
BACKGROUND: Previous research has indicated that there may be a link between Crohn's disease (CD) and breast cancer (BC), but the causality remains unclear. This study aimed to investigate the causal association between CD and BC using Mendelian randomization (MR) analysis. METHODS: The summary data for CD (5,956 cases/14,927 controls) …
Vitamin K: Infection, Inflammation, and Auto-Immunity
Publication Year: 2024 Source: J Inflamm Res PMID: 38406326
No Abstract
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East
Publication Year: 2024 Source: Therap Adv Gastroenterol PMID: 38406794 DOI: 10.1177/17562848241230902
BACKGROUND: A growing body of evidence underscores the beneficial impact of therapeutic drug monitoring (TDM) on the efficacy and cost-effectiveness of anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD). OBJECTIVES: We surveyed clinician attitudes, perceptions and barriers related to TDM in IBD in the Middle East. …
Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
Publication Year: 2024 Source: Therap Adv Gastroenterol PMID: 38406796 DOI: 10.1177/17562848241228080
Subcutaneous vedolizumab has demonstrated efficacy as a maintenance therapy in inflammatory bowel disease (IBD). However, data on the extension of subcutaneous vedolizumab injection intervals are lacking. Here, we present the first real-world data on subcutaneous vedolizumab interval extension in IBD patients. Nine patients (eight Crohn's disease patients and one ulcerative …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide